Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0038362 (stomatitis)
 8,852 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Bromodeoxyuridine (BUdR) is a radiosensitizer that can be incorporated into cellular DNA as a substitute for thymidine at the time of DNA synthesis. As the steady-state arterial concentration of BUdR given by means of intravenous infusion was recently presented, the possibility of revival of BUdR as a radiosensitizer administered by the intravenous route was suggested. Based on the experience of BAR therapy and phase-I studies by NIH and UCSF, 12 hours of BUdR at a dose of 800-1,000 mg/m2 for five days a week was given to 23 patients with primary and secondary malignant brain tumors during radiation therapy. Radiation therapy was planned at a weekly dose of 10 Gy for five to six weeks. Fifteen patients received 1,000 mg/m2 of BUdR; six of them tolerated more than three weeks of treatment. In eight patients given doses of 800 mg/m2, five patients tolerated more than three weeks. The most remarkable toxic effects were myelosuppression and stomatitis, which were major obstacles to maintaining the schedule. More than 50% reduction of tumor volume was obtained in five of 12 cases of evaluated gliomas (42%) and three of four cases of metastatic tumors (75%). The median time to tumor progression in seven patients with glioblastoma was 37 weeks.
 ...
PMID:Clinical trial of intravenous infusion of bromodeoxyuridine (BUdR) for radiosensitization of malignant brain tumors. 304 98

The HMB-2 human melanoma cell line derived from a lymph node metastatis is described. After long-term cultivation in vitro the cells retained their morphology, high growth rate, xenotransplantability into immunosuppressed mice and genotypic and phenotypic markers of human melanoma cells. Upon infection of the HMB-2 cells with temperature-sensitive mutant vesicular stomatitis virus (VSVts045) at nonpermissive temperature, a complemented virus pseudotype (VSV(HMB-2] was produced carrying assembled melanoma-associated antigens. Monoclonal antibodies prepared against HMB-2 cell membrane proteins and proteins of purified VSV(HMB-2) particles showed different reactivity with various human tumor cell lines and tissues: While the RG-12 anti-HMB-2 monoclonal antibody recognized a class II tumor-associated antigen present in melanoma and carcinoma tissues, the B-6 anti-VSV(HMB-2) antibody showed selective reactivity with melanoma cells.
 ...
PMID:Biological and immunological properties of the HMB-2 human melanoma cell line. 306 55

Autologous bone marrow transplantation to avoid dose-limiting myelosuppression may allow significant drug dose escalations and exploitation of the linear-log correlation between chemotherapy and tumor cytotoxicity. In a phase I trial of cyclophosphamide and thiotepa (with subsequent addition of melphalan), 23 patients were entered; there were two deaths due to toxic effects. The maximum tolerated dose was 6 g of cyclophosphamide/m2 and 720 mg of thiotepa/m2. No significant dose of melphalan could be added. Stomatitis was dose limiting. Eleven of 20 patients who were able to be evaluated responded. Plasma thiotepa concentrations correlated more closely with toxicity and response than with drug dose level. Continuous infusion cyclophosphamide and thiotepa is an active core regimen for the further design of high-dose combination chemotherapy regimens.
 ...
PMID:Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. 313 31

Twenty-three patients with metastatic adenocarcinomas were treated with long-term, continuous, ambulatory iv infusion of 5-FU. Length of infusion ranged from 54 to 324 days. The usual daily dose was 300 mg/m2. Toxicity was primarily stomatitis. Hand/foot syndrome occurred in 11 patients. Nausea, vomiting, myelosuppression, and alopecia were not observed. Thirteen patients had stomatitis. Eighteen patients had evaluable lesions; eight achieved partial response, five had stable disease, and five had progressive disease. Further studies are necessary to confirm the level of tumor response and survival period of patients treated with this method.
 ...
PMID:Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas. 315 49

A Phase I trial of pirarubicin (4'-O-tetrahydropyranyl-doxorubicin) was undertaken to study its toxicity and to gain preliminary knowledge of its efficacy. The dose was escalated by increments of 10 from 30 to 70 mg/m2. Out of 20 patients, 19 were evaluable for toxicity and response to treatment. Hematologic toxicity was dose limiting and dose related. Other adverse effects included nausea and vomiting, hair loss, and stomatitis. No acute cardiotoxicity was encountered. In 2 patients with metastatic breast cancer who had not been pretreated with cytostatic agents, a partial remission was achieved lasting for 5 months. In 6 patients, tumor parameters did not change for a median of 3 months, and 11 patients suffered progressive disease.
 ...
PMID:Phase I study of pirarubicin. 316 56

Methotrexate, Cisplatin, and Vinblastine (MCV) was followed by Cisplatin plus radiation therapy in 19 patients with muscle-invading clinical Stage T2-4NXM0 transitional cell carcinoma of the urinary bladder (including cystectomy candidates), to achieve local control and prevent distant metastases. Radical cystectomy was recommended for all patients who failed to reach a complete response (CR = biopsy negative and cytology not positive) following MCV and Cisplatin X 2 plus 4000 cGy. Completely responding patients, and those partially responding patients unsuited for cystectomy, were selected for bladder conservation treated with additional irradiation to the bladder tumor volume (total 6,480 cGy) plus one additional Cisplatin treatment. Dose reductions were required for stomatitis in 26%, mild bone marrow depression in 58%, and renal toxicity in 5% of the patients. During the Cisplatin/4000 cGy, mild dysuria occurred in 68% of patients and 36% had mild bowel hyperactivity. Serious complications have occurred in two patients to date. One patient had recurrent pulmonary emboli, marked reduction in bladder capacity, and diarrhea. A second had bladder perforation during cystoscopic evaluation after MCV and a small bowel obstruction after Cisplatin and 4000 cGy. There was no treatment-related sepsis. Three patients had initial complete transurethral resection of their tumors and therefore 16 patients are evaluable for tumor responsiveness to this protocol. Four patients (25%) were biopsy negative and cytology negative, whereas three additional patients (19%) were biopsy negative but cytology positive following initial MCV. Six patients (38%) were biopsy negative and cytology negative whereas three additional patients (19%) were biopsy negative and cytology positive following MCV and Cisplatin X 2 plus 4000 cGy pelvic radiation. Of the entire group, 9 patients were treated with full-dose radiotherapy. All of these patients are alive without evidence of tumor on rebiopsy of the original tumor site, but one has a persistent positive cytology. Seven patients had a radical cystectomy and 6 are disease free. The treatment of 3 patients deviated from the protocol. Overall, only one patient has developed distant metastases and currently 84% of the patients are disease-free, although follow-up is short. To date, this feasibility study has been clinically practical and well tolerated. The proportion of CR's suggests that this program may prove to be an organ-sparing and curative approach for a significant number of patients, but more experience and follow-up are required.
 ...
PMID:Invasive bladder carcinoma: preliminary report of selective bladder conservation by transurethral surgery, upfront MCV (methotrexate, cisplatin, and vinblastine) chemotherapy and pelvic irradiation plus cisplatin. 318 28

The psychological adaptation of the patient to neoplastic disease is based on various mechanisms related to the patient's personality, psychological resources, as well as to the available familial and social support. The various members of the care team play a major role: the nurses who are closest to the patient, the physicians who are the persons of reference, the psychologists and psychiatrists whose analysis and support help the patients in coping with the situation. Various methods are currently proposed to assess the psychological disorders and adaptation, but frequently, they have not been validated for the specific situation. Cancer therapies can induce major psychological disorders directly related to their side-effects: alopecia, stomatitis, gastro-intestinal toxicity, etc. Maximal care of these side-effects is important in order to prevent or reduce their psychological consequences. The psychological adaptation will also depend on the various phases of the disease: information at time of diagnosis must be adapted to patient's demand. The psychological support should be continuously offered, even during complete remission and return to normal life, which is often characterized by anxiety and fear of relapse. Consecutive relapses increase the feeling of precariousness and can lead to discouragement when a patient approaches the terminal phase.
 ...
PMID:[Psychological implications of cancer. II. Consequences of treatment and modality of adaptation]. 321 21

Between the 2 of january and the 31 of december 1985 there was done a study of 215 children in ages between 0-15 years in the Department of Oral Diagnosis of the Ibadan University Hospital, where they were external patients with oral infections/swelling. The male-female proportion was 1.3:1. 42.33% were from 0 to 5. 70.24% belonged to the lowest social group of the community, with a high risk of oral-facial infections. The situation of their oral hygiene didn't reflect their social and economical state, and meant no predisposition to infection. The common infections were alveolar abscess, acute necrotizing ulcerative gingivitis and primary herpetic gingivo-stomatitis. They could be complicated with measles and for nutritive failure. Neoplasms were uncommon. Infections were frequent in jaw; antibiotic therapy and "depridement" were often enough to eliminate them.
 ...
PMID:The incidence and pattern of oro-facial infection and swellings in Nigerian children. 327 95

Cyclopentenylcytosine (CPE-C, 2), a pyrimidine analogue of the fermentation derived carbocyclic nucleoside neplanocin A, has been synthesized from the optically active cyclopentenylamine 3b by two synthetic routes. CPE-C demonstrates significant antitumor activity against both the sensitive and ara-C resistant lines of L1210 leukemia in vivo. Multiple long term survivors are produced in both tumor models. The compound also gives 100% growth inhibition of the solid human A549 lung and MX-1 mammary tumor xenografts grown in athymic mice. Good activity is also observed against a third human tumor xenograft model, metastatic LOX melanoma. CPE-C has significant activity against both DNA and RNA viruses in vitro. Potent activity is observed against HSV-1 (TK+ and TK-), HSV-2, vaccinia, cytomegalovirus, and varicella-zoster virus. Good activity is also found against a strain of influenza virus (Hong Kong flu), vesicular stomatitis virus, Japanese encephalitis virus, and Punta Toro virus.
 ...
PMID:Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties. 341 97

The North Central Cancer Treatment Group (NCCTG) and Mayo Clinic are collaborating in an ongoing, prospective, randomized clinical trial of new approaches to the chemotherapy of advanced metastatic colorectal cancer. Single agent 5-fluorouracil (FUra) given by intensive-course rapid intravenous administration serves as a control. Included among the experimental treatments are two regimens consisting of FUra plus leucovorin (folinic acid). One of these regimens uses folinic acid at a dose level of 200 mg/m2 daily for 5 days based on earlier studies by Machover et al. (4). The second regimen uses folinic acid at 1/10 the dose level (20 mg/m2 daily for 5 days), since this lower dose of folinic acid has been shown to produce peak serum levels equivalent to the concentration of folinic acid required in culture medium to produce optimal inhibition of L1210 cells by FUra in vitro, and because of the great expense of folinic acid when given at the higher dose levels. As of January 1986, 78 patients had been randomized to receive treatment with FUra alone or one of the FUra-folinic acid regimens. The toxicity of the folinic acid regimens has been clinically tolerable, with stomatitis and, to a lesser extent, diarrhea being dose-limiting. Hematologic toxicity has been very mild. There is suggestive evidence that folinic acid given at the higher dose level in combination with FUra at a constant dose produces more severe effects on the oropharyngeal mucosa. Preliminary tumor response and survival data remain blinded in accordance with NCCTG policy. Further patient accrual and follow-up are required to assess the therapeutic effect of these folinic acid regimens compared to FUra given alone.
 ...
PMID:Clinical studies of biochemical modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer by the North Central Cancer Treatment Group and Mayo Clinic. 350 40


<< Previous 1 2 3 4 5 6 7 8 9 10